{"title":"Research progress of early/prefibrotic primary myelofibrosis","authors":"Zhiyang Liu, Xu-liang Shen","doi":"10.3760/CMA.J.ISSN.1673-419X.2018.06.009","DOIUrl":null,"url":null,"abstract":"Early/prefibrotic primary myelofibrosis (pre-PMF) is an early stage of primary myelofibrosis (PMF). It is a myeloproliferative neoplasms (MPN) with inert clinical manifestations and good prognosis. Diagnosis of pre-PMF mainly depends on bone marrow morphology and secondary clinical criteria. Patients with Pre-PMF have a better prognosis than those of PMF patients. This article reviews the research progress of bone marrow morphology, clinical and laboratory characteristics, gene mutation and load, treatment and prognosis of pre-PMF in order to improve understanding and diagnosis of the disease. \n \n \nKey words: \nPrimary myelofibrosis; Megakaryocytes; Gene expression regulation; Drug therapy; Hematopoietic stem cell transplantation; Prognosis","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"41 1","pages":"511-514"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2018.06.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Early/prefibrotic primary myelofibrosis (pre-PMF) is an early stage of primary myelofibrosis (PMF). It is a myeloproliferative neoplasms (MPN) with inert clinical manifestations and good prognosis. Diagnosis of pre-PMF mainly depends on bone marrow morphology and secondary clinical criteria. Patients with Pre-PMF have a better prognosis than those of PMF patients. This article reviews the research progress of bone marrow morphology, clinical and laboratory characteristics, gene mutation and load, treatment and prognosis of pre-PMF in order to improve understanding and diagnosis of the disease.
Key words:
Primary myelofibrosis; Megakaryocytes; Gene expression regulation; Drug therapy; Hematopoietic stem cell transplantation; Prognosis
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
